Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.15 AUD
Change Today 0.00 / 0.00%
Volume 0.0
PGL On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 9:06 PM 03/25/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Leslie Tillack BSc BE (Chem)

Chief Executive Officer of PharmaSynth Pty Ltd, Progen Pharmaceuticals Limited
AgeTotal Calculated CompensationThis person is connected to 5 board members in 1 different organizations across 2 different industries.

See Board Relationships
--A$174,203
As of Fiscal Year 2014

Background*

Mr. Leslie Tillack, also known as Les, BSc, BE (Chem) has been the Chief Executive Officer of PharmaSynth Pty Ltd since 2008. at Progen Pharmaceuticals Limited. Mr. Tillack has been with Progen Pharmaceuticals for 11 years, overseen Progen's anti cancer drug PI-88s progression from preclinical to phase 3 manufacture and has also been responsible for the tech transfer and manufacture of many client products for both clinical applications and marketed products. Prior to ...

Read Full Background

Corporate Headquarters*

2806 Ipswich Road
Darra, Queensland 4076

Australia

Phone: 61 7 3273 9133
Fax: 61 7 3375 1168

Board Members Memberships*

Chief Executive Officer and Director

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

SalaryA$140,828
BonusA$5,484
Total Annual CompensationA$146,312

Stock Options*

All Other CompensationA$16,447
Exercisable Options20,000
Unexercisable Options80,000
Total Number of Options100,000

Total Compensation*

Total Annual Cash CompensationA$162,759
Total Short Term CompensationA$146,312
Other Long Term CompensationA$16,447
Total Calculated CompensationA$174,203
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGL:AU A$0.15 AUD 0.00

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGEN PHARMACEUTICALS LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.